Document is current

Article History

Received: 9 January 2026

Accepted: 19 March 2026

First Online: 27 March 2026

Declarations

:

: The ethical boards of all treating affiliations approved the study which was conducted in accordance with the declaration of Helsinki and ICH Harmonized Tripartite Guideline for Good Clinical Practice. All patients gave written informed consent before inclusion and had the right to withdraw consent at any time.

: Not applicable.

: Loskog, Eriksson, Sandin, and Nordström are present or former employees of Lokon Pharma AB. Loskog is a board member of Lokon Pharma AB, Repos Pharma AB, Lynxalo AB and Medivir AB (Publ) and alternate board member of Nexttobe AB, Promegranate Veterinary AB and Almo Alo AB. Further, she is the inventor of a patent owned by Lokon Pharma AB in regard to LOAd703. Loskog and Lövgren holds a research grant from Lokon Pharma AB. The remaining authors declare no conflicts of interest.